Phase I Clinical trial of personalized peptide vaccine in combination with humanized anti-IL6 receptor monoclonal antibody for refractory colorectal cancer patients
Ontology highlight
ABSTRACT: Interventions: Anti-IL6 receptor antibody [Actemra (tocilizumab), Chugai Pharmaceutical Co; 0.5mg/kg (n=6), 2mg/kg (n=6), or 8mg/kg (n=6)] is intravenously administrated. After three days, a maximum of 4 peptides (3 mg/each peptide), which are selected based on the results of HLA typing and peptide-specific IgG titers, are subcutaneously administrated with incomplete Freund’s adjuvant (Montanide ISA51, Seppic)once a week for consecutive 6 weeks. During the treatment, safety is evaluated.The dose of anti-IL6 receptor antibody is escalated, if the safty is confirmed in 6 independent patients at the same dose.
Primary outcome(s): Safety (adverse events) of personalized peptide vaccine in combination with anti-IL6 receptor antibody.
Study Design: Single arm Non-randomized
DISEASE(S): Colorectal Cancer Patients Refractory To Conventional Treatments
PROVIDER: 2622910 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA